Eli Lilly posted a net profit of $7.1bn for the second quarter of 2026, a 25% increase from the $5.7bn recorded a year earlier, as sales of its GLP-1 drugs Mounjaro and Zepbound continued to surge. Revenue rose 48% year-on-year to $23bn, the company said on 5 August, with Mounjaro alone contributing $9.9bn — a 91% jump — and Zepbound adding $4.9bn, up 46%. The volume of medicines sold increased 60%, offsetting a 13% decline in average realised prices. Eli Lilly raised its full-year revenue forecast to between $85bn and $87bn, from a previous range of $82bn to $85bn.

The breakdown of revenue by geography is disputed in the supplied material. According to a Global News report citing chief financial officer Lucas Montarce, US revenue grew 48% and revenue in the rest of the world rose 136%, driven by Mounjaro in Latin America and Asia. However, reports from Valor Econômico and Poder360 both state that US revenue advanced 33% to $14.4bn and international revenue increased 80% to $8.6bn. The supplied articles do not explain the discrepancy.

Eli Lilly’s chief executive David A. Ricks said the company’s “positive trajectory continues”. The firm cemented its position as market leader in the GLP-1 segment: Montarce noted that in the second quarter approximately six out of ten total prescriptions and seven out of ten injectable prescriptions were for a Lilly medicine. Rival Novo Nordisk also reported an 11% rise in operating profit, with sales of its oral Wegovy pill meeting analyst expectations, though some analysts described the performance as “slightly soft”. Both companies face competition from generic GLP-1 drugs entering the Canadian market, where Eli Lilly’s international president Patrik Jonsson said the firm was “pleasantly surprised” by its performance, while noting that generic players have faced “significant supply constraints”.

Eli Lilly also announced an additional $4.5bn investment to expand production facilities in Indiana. The next factual milestone to watch is the company’s full-year results, for which it has raised its revenue guidance, and any further regulatory or competitive developments in the GLP-1 market.